Navigation Links
SeraCare Life Sciences Divests Biorepository Business

Milford, Massachusetts (PRWEB) January 03, 2013

SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, today announced that it has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings, Inc. This Maryland-based business includes biorepository and biobanking services, AccuCell® products and certain laboratory services.

“The sale of our Biorepository business is an important element in our growth strategy for SeraCare,” said Charles Mamrak, CEO of SeraCare. “We can now more freely serve our growing customer base in the in vitro diagnostics market and execute on our mission of improving quality of life by advancing a global understanding of disease.”

The transaction includes the transfer of Biorepository assets and employees. Financial terms of the transaction were not disclosed. SeraCare Life Sciences was advised by BroadOak Partners LLC and Kirkland & Ellis LLP during the transaction.

About SeraCare Life Sciences, Inc.
SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at

# # #

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SeraCare Life Sciences Sharpens Focus on Diagnostics Industry
2. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
3. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
4. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
5. 1DegreeBio Expands its Product Review Platform Across Life Sciences
6. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
7. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
8. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
(Date:10/9/2017)... ... 2017 , ... At its national board meeting in North Carolina, ARCS® ... Departments of Physics and Astronomy, has been selected for membership in ARCS Alumni ... the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):